<DOC>
	<DOCNO>NCT02280902</DOCNO>
	<brief_summary>Infections represent first cause death morbidity people treat immunologic inflammatory disease corticosteroid , immunosuppressive drug biotherapy . Epidemiological , clinical , biological therapeutic determinant infection poorly understood . There recommendation prevention treatment infection particular field . Purpose : Recent therapeutic trial evaluate immunosuppressive biotherapy ( cyclophosphamide , mycophenolate mofetil , rituximab , belimumab ) field immunologic inflammatory disease find risk severe infection 7 18 % first year begin treatment . Thus , main objective study describe incidence risk-factors infection people treat agent immunologic inflammatory disease .</brief_summary>
	<brief_title>Incidence Risk Factors Infections Patient Treated With Corticosteroids , Immunosuppressive Drugs Biotherapy Immunologic Inflammatory Diseases</brief_title>
	<detailed_description>Monitoring neutrophil , lymphocyte , immune activation marker , immunoglobulin prospectively study patient . Preliminary retrospective study show total lymphopenia independently associate increase risk infection . A previous retrospective study group also show total lymphopenia CD3- lymphopenia three month begin rituximab associate infection . The determinant infection occur course immune inflammatory disease treat corticoid immunosuppressive drug biotherapy probably multiple . We hypothesize follow variable may impact risk infection patient : Epidemiological : gender , social situation , Clinical : causal disease , comorbidities , vaccination status , Therapeutic : type dose corticosteroid immunosuppressive drugs/biotherapy , prevention treatment Biological : neutrophil , total lymphocyte , CD4-T lymphocytes , CD8-T lymphocytes , B lymphocytes , immune activation ( HLA-DR+ lymphocyte ) , CD5 CD19 lymphocytes , CD27/IgD lymphocytes , immunoglobulins IgA , IgM , IgG . On side , impact infection clinical course immunologic inflammatory disease poorly describe document longitudinal study . After inclusion present study , patient follow 30 month period monitor M3 , M6 , M12 , M24 describe impact treatment clinical biological variable . Every clinical event prospectively report validated specific committee .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Age &gt; 18 year Immune inflammatory disease : Lupus , antiphospholipid syndrome , Sjogren syndrome , inflammatory myositis , immunologic thrombopenic purpura , autoimmune hemolytic anemia , Evan 's syndrome , systemic vasculitis , Behcet disease . Indication corticosteroid therapy &gt; 20 mg least 3 month and/or immunosuppressive biologic agent . Information consent Previous treatment immunosuppressive biological agent , corticosteroid &gt; 3mois year precede inclusion Splenectomy Pregnancy Evoluting Cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>auto-immune disease</keyword>
	<keyword>inflammatory disease</keyword>
	<keyword>risk factor</keyword>
	<keyword>infection</keyword>
	<keyword>cohort study</keyword>
</DOC>